Neutralizing antibody responses to HIV: Role in protective immunity and challenges for vaccine design

Expert Review of Vaccines

Volumn 3, Issue 4 SUPPL., 2004, Pages

  Srivastava, Indresh K ^a   Ulmer, Jeffrey B ^a   Barnett, Susan W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CD4; HIV; Monomer; Neutralizing antibodies; Trimer

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION CONTROL; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 4344573018     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.S33     Document Type: Review

References (185)

1. Mascola JR et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus Type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173(2), 340-348 (1996).
2. Mascola JR et al. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses 9(12), 1175-1184 (1993).
3. Barouch DH, Letvin NL. Viral evolution and challenges in the development of HIV vaccines. Vaccine 20(Suppl. 4), A66-A68 (2002).
4. Barouch DH et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415(6869), 335-339 (2002).
5. Barouch DH et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77(13), 7367-7375 (2003).
6. Vogel TU et al. Multispecific vaccine-induced mucosal cytotoxic T-lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77(24), 13348-13360 (2003).
7. Mascola JR et al. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77(19), 10348-10356 (2003).
8. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171(6), 1387-1398 (1995).
9. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19(15-16), 1837-1848 (2001).
10. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13(4), 602-614 (2000).
11. Klasse PJ, Sattentau QJ. Mechanisms of virus neutralization by antibody. Curr. Top. Microbiol. Immunol. 260, 87-108 (2001).
12. Chan DC, Kim PS. HIV entry and its inhibition. Cell 93(5), 681-684 (1998).
13. Gorny MK, Zolla-Pazner S, Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus Type 1 gp41. J. Virol. 74(13), 6186-6192 (2000).
14. Golding H et al. Dissection of human immunodeficiency virus Type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76(13), 6780-6790 (2002).
15. Binley JM et al. Redox-triggered infection by disulfide-shadded human immunodeficiency virus Type 1 pseudovirions. J. Virol. 77(10), 5678-5684 (2003).
16. Hansen JE et al. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J. Virol. 64(6), 2833-2840 (1990).
17. Scanlan CN et al. The broadly neutralizing antihuman immunodeficiency virus Type 1 antibody 2G12 recognizes a cluster of alphal- > 2 mannose residues on the outer face of gp120. J. Virol. 76(14), 7306-7321 (2002).
18. Ugolini S et al. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T-cell line-adapted HIV-1 neutralization. J. Exp. Med. 186(8), 1287-1298 (1997).
19. Liao HX et al. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV Type 1 gp120 envelope glycoproteins. J. Virol. 78(10), 5270-5278 (2004).
20. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 10(2), 258-266 (1996).
21. Ahmad R et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating antiHIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21(3), 227-233 (2001).
22. Gomez-Roman VR et al. Phage-displayed mimotopes recognizing a biologically active antiHIV-1 gp120 murine monoclonal antibody. J. Acquir. Immune Defic. Syndr. 31(2), 147-153 (2002).
23. Spear GT et al. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204(2), 609-615 (1994).
24. Sawyer LA et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6(3), 341-356 (1990).
25. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV Type 1 in the presence of natural-killer effector cells. J. Virol. 75(15), 6953-6961 (2001).
26. Ljunggren K et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J. Infect. Dis. 161(2), 198-202 (1990).
27. Dimmock NJ. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183, 1-149 (1993).
28. Cao Y et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus Type 1 infection. N. Engl. J. Med. 332(4), 201-208 (1995).
29. Ho DD et al. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61(6), 2024-2028 (1987).
30. Moog C et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus Type 1-infected individuals. J. Virol. 71(5), 3734-3741 (1997).
31. Montefiori DC et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus Type 1 in long-term nonprogressors. J. Infect. Dis. 173(1), 60-67 (1996).
32. Moore JP et al. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68(1), 469-484 (1994).
33. Pilgrim AK et al. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176(4), 924-932 (1997).
34. Wrin T et al. Neutralizing antibody responses to autologous and heterologous isolares of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 7(3), 211-219 (1994).
35. Pilgrim AK et al. Neutralizing antibody responses to human immunodeficiency virus Type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176(4), 924-932 (1997).
36. Watkins BA et al. Resistance of human immunodeficiency virus Type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J. Virol. 70(12), 8431-8437 (1996).
37. Richman DD et al. Rapid evolution of the neutralizing antibody response to HIV Type 1 infection. Proc. Natl Acad. Sci. USA 100(7), 4144-4149 Epub 2003 Mar 18 (2003).
38. We X et al. Antibody neutralization and escape by HIV-1. Nature 422(6929), 307-312 (2003).
39. Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus Type 1 are highly prevalent in sera of infected humans. J. Virol. 67(2), 863-875 (1993).
40. VanCott TC et al. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155(8), 4100-4110 (1995).
41. Johnson WE, Desrosiers RC. Viral persistance: HIVs strategies of immune system evasion. Ann. Rev. Med. 53, 499-518 (2002).
42. Stamatos NM et al. Neutralizing antibodies from the sera of human immunodeficiency virus Type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J. Virol. 72(12), 9656-9667 (1998).
43. Steimer KS et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254, 105-108 (1991).
44. Barbas CF 3rd et al. Recombinant human Fab fragments neutralize human Type 1 immunodeficiency virus in vitro. Proc. Natl Acad. Sci. USA 89(19), 9339-9343 (1992).
45. Thali M et al. Characterization of conserved human immunodeficiency virus Type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67(7), 3978-3988 (1993).
46. Trkola A et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus Type 1. J. Virol. 70(2), 1100-1108 (1996).
47. Fung MS et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus Type 1 gp120. J. Virol. 66(2), 848-856 (1992).
48. Gorny MK et al. Human antiV2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus Type 1. J. Virol. 68(12), 8312-8320 (1994).
49. Javaherian K et al. Principal neutralizing domain of the human immunodeficiency virus Type 1 envelope protein. Proc. Natl Acad. Sci. USA 86(17), 6768-6772 (1989).
50. Putney SD et al. HTLV-III/LAV-neutralizing antibodies to an E coli-produced fragment of the virus envelope. Science 234(4782), 1392-1395 (1986).
51. Gorny MK et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus Type 1 envelope glycoprotein. Proc Natl Acad. Sci. USA 88(8), 3238-3242 (1991).
52. Goudsmit J. Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. AIDS 2(Suppl. 1), S41-S45 (1988).
53. Xu JY et al. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus Type 1, using ten human monoclonal antibodies. J. Virol. 65(9), 4832-4838 (1991).
54. Binley JM et al. Human antibody responses to HIV Type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retroviruses 12(10), 911-924 (1996).
55. Karwowska S et al. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitope of gp120. AIDS Res. Hum. Retroviruses 8(6) 1099-1106 (1992).
56. Pinter A et al. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res. Hum. Retroviruses 9(10), 985-996 (1993).
57. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunol. Today 17(5), 239-246 (1996).
58. Trkola A et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69(11), 6609-6617 (1995).
59. Kessler JA 2nd et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus Type 1 primary isolates. AIDS Res. Hum. Retroviruses 13(7), 575-582 (1997).
60. Hioe CE et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9(9), 1281-1290 (1997).
61. D'Souza MP et al. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9(8), 867-874 (1995).
62. Roben P et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus Type 1. J. Virol. 68(8), 4821-4828 (1994).
63. Hioe CE et al. AntiCD4-binding domain antibodies complexed with HIV Type 1 glycoprotein 120 inhibit CD4+ T-cell-proliferative responses to glycoprotein 120. AIDS Res. Hum. Retroviruses 16(9), 893-905 (2000).
64. Hioe CE et al. Inhibition of human immunodeficiency virus Type 1 gp120 presentation to CD4 T-cells by antibodies specific for the CD4 binding domain of gp120. J. Virol. 75(22), 10950-10957 (2001).
65. Chien PC Jr et al. Human immunodeficiency virus Type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J. Virol. 78(14), 7645-7652 (2004).
66. Feng Y et al. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science 272(5263), 872-877 (1996).
67. Alkhatib G et al. Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/ cytoplasmic regions. J. Biol. Chem. 272(33), 20420-20426 (1997).
68. Deng H et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381(6584), 661-666 (1996).
69. Xiang SH et al. Characterization of CD4-induced epitopes on the HIVType 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18(16), 1207-1217 (2002).
70. Moulard M et al. Broadly cross-reactive HTV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl Acad. Sci. USA 99(10), 6913-6918 (2002).
71. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus Type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 77(5), 2859-2865 (2003).
72. Sullivan N et al. CD4-Induced conformational changes in the human immunodeficiency virus Type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72(6), 4694-4703 (1998).
73. Sodroski J. Retroviruses of Human AIDS and Related Animal Diseases. M Vicari (Ed.), Elsevier, France (2002).
74. Leonard CX et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the Type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265(18), 10373-10382 (1990).
75. Abrignani S et al. Priming of CD4+ T-cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc. Natl Acad. Sci. USA 87(16), 6136-6140 (1990).
76. Haigwood NL et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6(7), 855-869 (1990).
77. Wyatt R et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686), 705-711 (1998).
78. Sanders RW et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus Type 1 glycoprotein gp120. J. Virol. 76(14), 7293-7305 (2002).
79. Bures R et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus Type 1 from South Africa. J. Virol. 76(5), 2233-2244 (2002).
80. Calarese DA et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300(5628), 2065-2071 (2003).
81. Robinson HL. New hope for an AIDS vaccine. Nature Rev. Immunol. 2(4), 239-250 (2002).
82. Cao J et al. Replication and neutralization of human immunodeficiency virus Type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71(12), 9808-9812 (1997).
83. Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus Type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72(10), 7840-7845 (1998).
84. Center RJ et al. The human immunodeficiency virus Type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 74(10), 4448-4455 (2000).
85. Rizzuto CD et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280(5371), 1949-1953 (1998).
86. Wyatt R et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus Type 1 gp120 epitopes induced by receptor binding. J. Virol. 69(9), 5723-5733 (1995).
87. Wyatt R et al. Functional and immunologic characterization of human immunodeficiency virus Type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67(8), 4557-4565 (1993).
88. Derdeyn CA et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303(5666), 2019-2022 (2004).
89. Srivastava IK et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77(4), 2310-2320 (2003).
90. Kwong PD et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686), 648-659 (1998).
91. Kwong PD et al. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74(4), 1961-1972 (2000).
92. Stanfield RL et al. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (Camb.) 12(2), 193-204 (2004).
93. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus Type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76(17), 8953-8957 (2002).
94. Suphaphiphat P et al. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus Type 1 subtype C gp120 on CCR5 utilization. J. Virol. 77(6), 3832-3837 (2003).
95. Sharon M et al. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb.) 11(2), 225-236 (2003).
96. Yonezawa A et al. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus Type 1. J. Virol. 75(9), 4258-4267 (2001).
97. Goudsmit J et al. Human immunodeficiency virus Type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl Acad. Sci. USA 85(12), 4478-4482 (1988).
98. Gorny MK et al. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunol. 159(10), 5114-5122 (1997).
99. Gorny MK et al. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150(2), 635-643 (1993).
100. Conley AJ et al. Neutralization of primary human immunodeficiency virus Type 1 isolates by the broadly reactive antiV3 monoclonal antibody, 447-52D. J. Virol. 68(11), 6994-7000 (1994).
101. Krachmarov CP et al. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus Type 1. AIDS Res. Hum. Petroviruses 17(18), 1737-1748 (2001).
102. Poignard P et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus Type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77(1), 353-365 (2003).
103. Gorny MK et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus Type 1 primary isolates from various clades. J. Virol. 76(18), 9035-9045 (2002).
104. Andris JS et al. Molecular characterization of five human antihuman immunodeficiency virus Type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response. Proc. Natl Acad. Sci. USA 88(17), 7783-7787 (1991).
105. Choe H et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114(2), 161-170 (2003).
106. Parker CE et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus Type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75(22), 10906-10911 (2001).
107. Zwick MB et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing antihuman immunodeficiency virus Type 1 antibody b12. J. Virol. 75(14), 6692-6699 (2001).
108. Coeffier E et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19(7-8), 684-693 (2000).
109. Zwick MB et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus Type 1 glycoprotein gp41. J. Virol. 75(22), 10892-10905 (2001).
110. Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206(1), 713-717 (1995).
111. Zolla-Pazner S et al. Serotyping of primary human immunodeficiency virus Type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69(6), 3807-3815 (1995).
112. Nyambi PN et al. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus Type 1 virions of group M J. Virol. 74(15), 7096-7107 (2000).
113. Cotropia J et al. A human monoclonal antibody to HIV-1 gp41 with neutralising activity against diverse laboratory isolates. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12(3), 221-232 (1996).
114. Ferrantelli F et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine. J. Infect. Dis. 189(1), 71-74 (2004).
115. Emini EA et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355(6362), 728-730 (1992).
116. Conley AJ et al. The consequence of passive administration of an antihuman immunodeficiency virus Type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70(10), 6751-6758 (1996).
117. Mosier DE et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335(6187), 256-259 (1988).
118. Mosier DE et al. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251(4995), 791-794 (1991).
119. Safrit JT et al. hu-PBL-SCID mice can be protected from HIV-1 infection bypassive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 7(1), 15-21 (1993).
120. Gauduin MC et al. Pre- and postexposure protection against human immunodeficiency virus Type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171(5), 1203-1209 (1995).
121. Parren PW et al. Protection against HIV-1 infection in hu-PBL-SCID mice bypassive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9(6), F1-F6 (1995).
122. Parren PW et al. Erratum to 'Relevance of the antibody response against human immunodeficiency virus Type 1 envelope to vaccine design'. Immunol. Lett. 58(2), 125-132 (1997).
123. Parren PW et al. Erratum to 'Relevance of the antibody response against human immunodeficiency virus Type 1 envelope to vaccine design'. Immunol. Lett. 58(2), 125-132 (1997).
124. Mosier DE. Distinct rate and patterns of human CD4+ T-cell depletion in hu-PBL-SCID mice infected with different isolates of the human immunodeficiency virus. J. Clin. Immunol. 15(6 Suppl.), 1305-1335 (1995).
125. Mascola JR et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD bypassive transfer of neutralizing antibodies. J. Virol. 73(5), 4009-4018 (1999).
126. Mascola JR et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus bypassive infusion of neutralizing antibodies. Nature Med. 6(2), 207-210 (2000).
127. Nishimura Y et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA 100(25), 15131-15136 (2003).
128. Hofmann-Lehmann R et al. Postnatal pre-and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J. Med. Primatol. 31(3), 109-119 (2002).
129. Safrit JT et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35(2), 169-177 (2004).
130. Ruprecht RM et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8(4), 350-358 (2001).
131. Ferrantelli F et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17(3), 301-309 (2003).
132. Francis DP et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first Phase III efficacy trials. AIDS 17(2), 147-156 (2003).
133. Fouts TR et al. Interaction of polyclonal and monoclonal antiglycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV Type 1 isolate relationship to neutralization. AIDS Res. Hum. Retroviruses 14, 591-597 (1997).
134. Sattentau QJ, Moore JP. Human immunodeficiency virus Type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182(1), 185-196 (1995).
135. Broder CC et al. Antigenic implications of human immunodeficiency virus Type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl Acad. Sci. USA 91(24), 11699-11703 (1994).
136. Earl PL et al. Native oligomeric human immunodeficiency virus Type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68(5), 3015-3026 (1994).
137. Earl PL, Koenig S, Moss B. Biological and immunological properties of human immunodeficiency virus Type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65(1), 31-41 (1991).
138. Earl PL et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus Type 1 gp140. J. Virol. 75(2), 645-653 (2001).
139. Srivastava IK et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J. Virol. 76(6), 2835-2847 (2002).
140. Srivastava IK et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus Type 1 isolate. J. Virol. 77(20), 11244-11259 (2003).
141. Binley JM et al. A recombinant human immunodeficiency virus Type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74(2), 627-643 (2000).
142. Faizan M et al. Stabilization of human immunodeficiency virus Type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J. Virol. 72(9), 7620-7625 (1998).
143. Sanders KW et al. Variable-loop-deleted variants of the human immunodeficiency virus Type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J. Virol. 74(11), 5091-5100 (2000).
144. Schulke N et al. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus Type 1 gp140 envelope glycoprotein. J. Virol. 76(15), 7760-7776 (2002).
145. Sanders RW et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus Type 1. J. Virol. 76(17), 8875-8889 (2002).
146. Yang X et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus Type 1 envelope glycoproteins. J. Virol. 74(12), 5716-5725 (2000).
147. Yang X et al. Highly stable trimers formed by human immunodeficiency virus Type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76(9), 4634-4642 (2002).
148. Earl PL, Doms RW, Moss B. Oligomeric structure of the human immunodeficiency virus Type 1 envelope glycoprotein. Proc. Natl Acad. Sci. USA 87(2), 648-652 (1990).
149. Earl PL, Moss B. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Ses. Hum. Retroviruses 9(7), 589-594 (1993).
150. Binley JM et al. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 270(1), 237-249 (2000).
151. VanCott TC et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus Type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71, 4319-4330 (1997).
152. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75(3), 1165-1171 (2001).
153. Barnett SW et al. The ability of an oligomeric human immunodeficiency virus Type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75(12), 5526-5540 (2001).
154. Cherpelis S et al. DNA vaccination with the human immunodeficiency virus Type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J. Virol. 75(3), 1547-1550 (2001).
155. Cherpelis S et al. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79(1-2), 47-55 (2001).
156. Buckner C et al. Priming B-cell-mediated antiHIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV Virology 320(1), 167-180 (2004).
157. Pal R et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A. Virology 194(2), 833-837 (1993).
158. Gershoni JM et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J. 7(12), 1185-1187 (1993).
159. DeVico AL et al. Monoclonal antibodies raised against covalentry crosslinked complexes of human immunodeficiency virus Type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology 211(2), 583-588 (1995).
160. Srivastava I, Kan E, Sharma V, Sun Y, Ulmer JB, Barnett SW. Induction of broadly cross-reactive primary isolate neutralizing antibodies by Env-CD4 complexes. 10th Conference on Retroviruses and Opportunistic Infections (2003).
161. Celada F et al. Antibody raised against soluble CD4-rgp 20 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J. Exp. Med. 172, 1143-1150 (1990).
162. Sweet RW, Truneh A, Hendrickson WA. CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Curr. Opin. Biotechnol. 2(4), 622-633 (1991).
163. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 267(5196), 383-386 (1995).
164. Vita C. Engineering novel proteins by transfer of active sites to natural scaffolds. Curr. Opin. Biotechnol. 8(4), 429-434 (1997).
165. Vita C et al. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. Biopolymers 47(1), 93-100 (1998).
166. Vita C et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl Acad. Sci. USA 96(23), 13091-13096 (1999).
167. Martin L et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nature Biotechnol. 21(1), 71-76 (2003).
168. Fouts T et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl Acad. Sci. USA 99(18), 11842-11847 (2002).
169. Pantophlet R et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus Type 1 gp120. J. Virol. 77(1), 642-658 (2003).
170. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) Type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77(10), 5889-5901 (2003).
171. Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus Type 1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72, 7840-7845 (1998).
172. Stamatatos L, Iim M, Cheng-Mayer C. Generation and structural analysis of soluble oligpmeric gp140 envelope proteins derived from neutralization- resistant and neutralization-susceptible primary HIV Type 1 isolates [In Process Citation]. AIDS Res. Hum. Retroviruses 16(10), 981-994 (2000).
173. Lu S, Wang S, Mascola J et al. Immunogenicity of monovalent and polyvalent DNA prime/protein boost formulations encoding primary HIV-1 Env ntigens as tested in rabbits and non-human primate models. Keystone Symposium on HIV Vaccine Development: Progress and Prospects. Whistler, British Columbia, Canada. Abstract 245 (2004).
174. Sambor A, Louder M, Welcher B et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing HIV-1 proteins. Keystone Symposium on HIV Vaccine Development: Progress and Prospects. Whistler, British Columbia, Canada. Abstract 306 (2004).
175. Weaver EA, Lu Z, Li Y et al. Cross-subtype immune responses of HIV-1 group M consensus Env immunogens. 11th Conference on Petrovirus and Opportunistic Infections. San Francisco, USA. Abstract 164 (2004).
176. Li Y, Weaver EA, Decker JM et al. In vitro and in vivo biological characteristics of subtype C consensus and ancesteral envelope immunogens. 11th Conference on Retrovirus and Opportunitic Infections. San Francisco, USA. Abstract 278 (2004).
177. Gaschen B et al. Diversity considerations in HIV-1 vaccine selection. Science 296(5577), 2354-2360 (2002).
178. Learn GH, Doria-Rose N, Mahalanabis M et al. Ancesteral HIV-1B Env protein induces broadly neutralizing antibodies in rabbits. 10th Conference on Retroviruses and Opportunitic Infections. Boston, Massachusetts. Abstract 409 (2003).
179. Richmond JF et al. Studies of the neutralizing activity and avidity of antihuman immunodeficiency virus Type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol. 72(11), p9092-100 (1998).
180. Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur 38, 1 (1924).
181. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design: The Subunit and Adjuvant Approach. MF Powell, MJ Newman (Eds), Plenum Press, New York 141-228 (1995).
182. O'Hagan DT et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20(27-28), 3389-3398 (2002).
183. O'Hagan D, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2(2), 269-283 (2003).
184. Singh M et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res. 18(10), 1476-1479 (2001).
185. Lanzavecchia A, Sallusto F. Regulation of T-cell immunity by dendritic cells. Cell 106(3), 263-266 (2001).